A citation-based method for searching scientific literature


List of co-cited articles
17 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The diagnostic approach to monogenic very early onset inflammatory bowel disease.
Holm H Uhlig, Tobias Schwerd, Sibylle Koletzko, Neil Shah, Jochen Kammermeier, Abdul Elkadri, Jodie Ouahed, David C Wilson, Simon P Travis, Dan Turner,[...]. Gastroenterology 2014
313
80

Clinical Genomics in Inflammatory Bowel Disease.
Holm H Uhlig, Aleixo M Muise. Trends Genet 2017
47
60

ACG Clinical Guideline: Management of Crohn's Disease in Adults.
Gary R Lichtenstein, Edward V Loftus, Kim L Isaacs, Miguel D Regueiro, Lauren B Gerson, Bruce E Sands. Am J Gastroenterol 2018
354
40

Analysis of Genes Associated With Monogenic Primary Immunodeficiency Identifies Rare Variants in XIAP in Patients With Crohn's Disease.
Leila Amininejad, Benoit Charloteaux, Emilie Theatre, Claire Liefferinckx, Julia Dmitrieva, Pierre Hayard, Vincianne Muls, Jean-Marc Maisin, Michael Schapira, Jean-Michel Ghislain,[...]. Gastroenterology 2018
15
40

Severe early-onset colitis revealing mevalonate kinase deficiency.
Michael Levy, Alina Arion, Dominique Berrebi, Laurence Cuisset, Corinne Jeanne-Pasquier, Brigitte Bader-Meunier, Camille Jung. Pediatrics 2013
34
40

AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy.
Bernice Lo, Kejian Zhang, Wei Lu, Lixin Zheng, Qian Zhang, Chrysi Kanellopoulou, Yu Zhang, Zhiduo Liu, Jill M Fritz, Rebecca Marsh,[...]. Science 2015
324
40

Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease.
Katrina M de Lange, Loukas Moutsianas, James C Lee, Christopher A Lamb, Yang Luo, Nicholas A Kennedy, Luke Jostins, Daniel L Rice, Javier Gutierrez-Achury, Sun-Gou Ji,[...]. Nat Genet 2017
344
40

Opportunities and challenges of whole-genome and -exome sequencing.
Britt-Sabina Petersen, Broder Fredrich, Marc P Hoeppner, David Ellinghaus, Andre Franke. BMC Genet 2017
83
40

Novel Mutations of the Tetratricopeptide Repeat Domain 7A Gene and Phenotype/Genotype Comparison.
Reyin Lien, Yung-Feng Lin, Min-Wei Lai, Hui-Ying Weng, Ren-Chin Wu, Tang-Her Jaing, Jing-Long Huang, Shih-Feng Tsai, Wen-I Lee. Front Immunol 2017
15
40

TTC7A mutations disrupt intestinal epithelial apicobasal polarity.
Amélie E Bigorgne, Henner F Farin, Roxane Lemoine, Nizar Mahlaoui, Nathalie Lambert, Marine Gil, Ansgar Schulz, Pierre Philippet, Patrick Schlesser, Tore G Abrahamsen,[...]. J Clin Invest 2014
95
40

Mutations in tetratricopeptide repeat domain 7A result in a severe form of very early onset inflammatory bowel disease.
Yaron Avitzur, Conghui Guo, Lucas A Mastropaolo, Ehsan Bahrami, Hannah Chen, Zhen Zhao, Abdul Elkadri, Sandeep Dhillon, Ryan Murchie, Ramzi Fattouh,[...]. Gastroenterology 2014
111
40

Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification.
Arie Levine, Anne Griffiths, James Markowitz, David C Wilson, Dan Turner, Richard K Russell, John Fell, Frank M Ruemmele, Thomas Walters, Mary Sherlock,[...]. Inflamm Bowel Dis 2011
767
40

Diagnostic Yield of Next-generation Sequencing in Very Early-onset Inflammatory Bowel Diseases: A Multicentre Study.
Fabienne Charbit-Henrion, Marianna Parlato, Sylvain Hanein, Rémi Duclaux-Loras, Jan Nowak, Bernadette Begue, Sabine Rakotobe, Julie Bruneau, Cécile Fourrage, Olivier Alibeu,[...]. J Crohns Colitis 2018
32
40

Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease.
Elizabeth A Worthey, Alan N Mayer, Grant D Syverson, Daniel Helbling, Benedetta B Bonacci, Brennan Decker, Jaime M Serpe, Trivikram Dasu, Michael R Tschannen, Regan L Veith,[...]. Genet Med 2011
474
40

Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations.
Jimmy Z Liu, Suzanne van Sommeren, Hailiang Huang, Siew C Ng, Rudi Alberts, Atsushi Takahashi, Stephan Ripke, James C Lee, Luke Jostins, Tejas Shah,[...]. Nat Genet 2015
968
40

Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease.
Eva Gonçalves Serra, Tobias Schwerd, Loukas Moutsianas, Athena Cavounidis, Laura Fachal, Sumeet Pandey, Jochen Kammermeier, Nicholas M Croft, Carsten Posovszky, Astor Rodrigues,[...]. Nat Commun 2020
16
40

Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies.
Jodie Ouahed, Elizabeth Spencer, Daniel Kotlarz, Dror S Shouval, Matthew Kowalik, Kaiyue Peng, Michael Field, Leslie Grushkin-Lerner, Sung-Yun Pai, Athos Bousvaros,[...]. Inflamm Bowel Dis 2020
22
40

Sphingosine-1-phosphate and its receptors: structure, signaling, and influence.
Hugh Rosen, Raymond C Stevens, Michael Hanson, Edward Roberts, Michael B A Oldstone. Annu Rev Biochem 2013
138
20

Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.
Gary R Lichtenstein, Brian G Feagan, Russell D Cohen, Bruce A Salzberg, Robert H Diamond, Samiyeh Price, Wayne Langholff, Anil Londhe, William J Sandborn. Am J Gastroenterol 2012
454
20

Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
Paul Rutgeerts, Brian G Feagan, Gary R Lichtenstein, Lloyd F Mayer, Stefan Schreiber, Jean Frederic Colombel, Daniel Rachmilewitz, Douglas C Wolf, Allan Olson, Weihang Bao,[...]. Gastroenterology 2004
709
20

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
Kristin K Jørgensen, Inge C Olsen, Guro L Goll, Merete Lorentzen, Nils Bolstad, Espen A Haavardsholm, Knut E A Lundin, Cato Mørk, Jørgen Jahnsen, Tore K Kvien. Lancet 2017
415
20

Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.
Remo Panaccione, Subrata Ghosh, Stephen Middleton, Juan R Márquez, Boyd B Scott, Laurence Flint, Hubert J F van Hoogstraten, Annie C Chen, Hanzhe Zheng, Silvio Danese,[...]. Gastroenterology 2014
509
20

A controlled trial of natalizumab for relapsing multiple sclerosis.
David H Miller, Omar A Khan, William A Sheremata, Lance D Blumhardt, George P A Rice, Michele A Libonati, Allison J Willmer-Hulme, Catherine M Dalton, Katherine A Miszkiel, Paul W O'Connor. N Engl J Med 2003
907
20

Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease.
A J Yarur, V Kanagala, D J Stein, F Czul, M A Quintero, D Agrawal, A Patel, K Best, C Fox, K Idstein,[...]. Aliment Pharmacol Ther 2017
134
20

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
William J Sandborn, Gert van Assche, Walter Reinisch, Jean-Frederic Colombel, Geert D'Haens, Douglas C Wolf, Martina Kron, Mary Beth Tighe, Andreas Lazar, Roopal B Thakkar. Gastroenterology 2012
727
20

Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation.
Shomron Ben-Horin, Niels Vande Casteele, Stefan Schreiber, Peter Laszlo Lakatos. Clin Gastroenterol Hepatol 2016
60
20

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.
L W Moreland, M H Schiff, S W Baumgartner, E A Tindall, R M Fleischmann, K J Bulpitt, A L Weaver, E C Keystone, D E Furst, P J Mease,[...]. Ann Intern Med 1999
20

Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease.
Joana Torres, Ray K Boyapati, Nicholas A Kennedy, Edouard Louis, Jean-Frédéric Colombel, Jack Satsangi. Gastroenterology 2015
114
20

Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study.
S Schreiber, I C Lawrance, O Ø Thomsen, S B Hanauer, R Bloomfield, W J Sandborn. Aliment Pharmacol Ther 2011
87
20

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Ludwig Kappos, Ernst-Wilhelm Radue, Paul O'Connor, Chris Polman, Reinhard Hohlfeld, Peter Calabresi, Krzysztof Selmaj, Catherine Agoropoulou, Malgorzata Leyk, Lixin Zhang-Auberson,[...]. N Engl J Med 2010
20

Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations.
Desirée Schubert, Claudia Bode, Rupert Kenefeck, Tie Zheng Hou, James B Wing, Alan Kennedy, Alla Bulashevska, Britt-Sabina Petersen, Alejandro A Schäffer, Björn A Grüning,[...]. Nat Med 2014
445
20

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Wolfgang Hueber, Bruce E Sands, Steve Lewitzky, Marc Vandemeulebroecke, Walter Reinisch, Peter D R Higgins, Jan Wehkamp, Brian G Feagan, Michael D Yao, Marek Karczewski,[...]. Gut 2012
875
20

Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials.
Kristian Reich, Craig Leonardi, Richard G Langley, Richard B Warren, Hervé Bachelez, Ricardo Romiti, Mamitaro Ohtsuki, Wen Xu, Nayan Acharya, Kathleen Solotkin,[...]. J Am Acad Dermatol 2017
56
20

Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain.
Daniel J Cua, Jonathan Sherlock, Yi Chen, Craig A Murphy, Barbara Joyce, Brian Seymour, Linda Lucian, Wayne To, Sylvia Kwan, Tatyana Churakova,[...]. Nature 2003
20

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
Geert R D'Haens, Remo Panaccione, Peter D R Higgins, Severine Vermeire, Miquel Gassull, Yehuda Chowers, Stephen B Hanauer, Hans Herfarth, Daan W Hommes, Michael Kamm,[...]. Am J Gastroenterol 2011
323
20

Inhibitory Smad7: emerging roles in health and disease.
Marco A Briones-Orta, Angeles C Tecalco-Cruz, Marcela Sosa-Garrocho, Cassandre Caligaris, Marina Macías-Silva. Curr Mol Pharmacol 2011
42
20

A review of the current use of rituximab in autoimmune diseases.
Hakan M Gürcan, Derin B Keskin, Joel N H Stern, Matthew A Nitzberg, Haris Shekhani, A Razzaque Ahmed. Int Immunopharmacol 2009
224
20

Integrin-based therapeutics: biological basis, clinical use and new drugs.
Klaus Ley, Jesus Rivera-Nieves, William J Sandborn, Sanford Shattil. Nat Rev Drug Discov 2016
195
20

Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.
Nathaniel R West, Ahmed N Hegazy, Benjamin M J Owens, Samuel J Bullers, Bryan Linggi, Sofia Buonocore, Margherita Coccia, Dieter Görtz, Sébastien This, Krista Stockenhuber,[...]. Nat Med 2017
248
20

Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.
Bruce E Sands, Richard Kozarek, Jack Spainhour, Charles F Barish, Scott Becker, Lawrence Goldberg, Seymour Katz, Ronald Goldblum, Rena Harrigan, Deborah Hilton,[...]. Inflamm Bowel Dis 2007
89
20


Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.
B Oppmann, R Lesley, B Blom, J C Timans, Y Xu, B Hunte, F Vega, N Yu, J Wang, K Singh,[...]. Immunity 2000
20

Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases.
Clara Abraham, Parambir S Dulai, Séverine Vermeire, William J Sandborn. Gastroenterology 2017
72
20

Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.
Nathaniel R West, Ahmed N Hegazy, Benjamin M J Owens, Samuel J Bullers, Bryan Linggi, Sofia Buonocore, Margherita Coccia, Dieter Görtz, Sébastien This, Krista Stockenhuber,[...]. Nat Med 2017
52
20

Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology.
Sofia Buonocore, Philip P Ahern, Holm H Uhlig, Ivaylo I Ivanov, Dan R Littman, Kevin J Maloy, Fiona Powrie. Nature 2010
766
20

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study.
Bruce E Sands, Jingjing Chen, Brian G Feagan, Mark Penney, William A Rees, Silvio Danese, Peter D R Higgins, Paul Newbold, Raffaella Faggioni, Kaushik Patra,[...]. Gastroenterology 2017
126
20

Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity.
Anne Puel, Sophie Cypowyj, Jacinta Bustamante, Jill F Wright, Luyan Liu, Hye Kyung Lim, Mélanie Migaud, Laura Israel, Maya Chrabieh, Magali Audry,[...]. Science 2011
654
20

Infliximab for induction and maintenance therapy for ulcerative colitis.
Paul Rutgeerts, William J Sandborn, Brian G Feagan, Walter Reinisch, Allan Olson, Jewel Johanns, Suzanne Travers, Daniel Rachmilewitz, Stephen B Hanauer, Gary R Lichtenstein,[...]. N Engl J Med 2005
20

Rituximab in active ulcerative colitis.
Elisabeth Calderón-Gómez, Julián Panés. Gastroenterology 2012
4
25



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.